M

Merck

Makes medicines, vaccines and animal treatments

Regulatory Compliance Specialist

Full-TimePosted on 10/22/2026Deadline 11/6/26
No salary listed
Senior
Bachelor's, Master's, PhD
Co. Carlow, Ireland
HybridHybrid work arrangement.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor's degree or higher, ideally in a related science discipline, is preferred.
  • Typically 5+ years' experience in Regulatory Affairs, Quality Assurance, and/or Regulatory Compliance within a GMP-regulated pharmaceutical or biologics manufacturing environment is preferred.
  • Demonstrated track record in CMC regulatory submissions, dossier preparation, and management of complex health authority question-and-answer cycles, including compilation and review of large volumes of supporting documentation.
  • Hands-on experience supporting technology transfer and new product introduction activities at a manufacturing site level, including coordination of regulatory documentation across functions.
  • Demonstrated experience managing licensing activities: Site Master File updates, MIA/IMP license maintenance, HPRA notifications, and market-specific accreditation submissions.
  • Experience designing and implementing regulatory tracking and knowledge-management systems that improve team performance, visibility, and business continuity.
  • Ability to manage high volumes of concurrent regulatory activities — ancillary document requests, RTQs, change controls, SMF updates — to demanding timelines without compromising quality.
  • In-depth knowledge of global regulatory frameworks: EMA, FDA, ICH guidelines, and Irish national requirements (HPRA).
  • Strong understanding of GMP requirements as they apply to regulatory compliance, change control classification, and quality systems.
  • Familiarity with pharmaceutical product development, validation, stability, and batch-release processes and their regulatory implications.
  • Proficiency in regulatory document management systems and electronic tracking tools.
Responsibilities
  • Comply with and execute CGMP/GDP in the performance of day-to-day business activities.
  • Ensure data integrity principles (Attributable, Legible, Contemporaneous, Original, and Accurate) are adhered to for records and data in day-to-day business activities.
  • Work collaboratively to drive a safe and compliant culture on site.
  • Manage regulatory requests that come to site, including preparing GMP dossiers to support new submissions; preparing ancillary documents required to support module 1 of regulatory dossiers in applicable markets; authoring and reviewing related responses to agency questions; preparing documentation to support product renewals, re-registrations, and tender bids; maintaining Japanese site accreditation; maintaining site GMP certificates and IMP/Commercial license; managing HPRA notifications for new product; and managing the site master file.
  • Quality review new product dossiers as part of BLA/MAA authoring.
  • Quality review post-approval change submissions.
  • Review applicable change controls to determine impact to local documentation and regulatory requirements.
  • Work collaboratively with site and above-site teams to resolve regulatory compliance issues.
  • Participate in relevant product team meetings.
  • Participate in NPI tech transfer workshops to identify regulatory compliance deliverables.
  • Support regulatory compliance metrics and reporting.
  • Ensure and promote that adequate processes and procedures are in place and followed for all Quality activities.
  • Liaise with the Quality/Business Area Specialists/QP/QA Lead and Quality Associate Specialist/Specialists to resolve quality-related queries where required.
  • Develop and maintain effective cross-functional relationships with other departments and support functions to ensure that the processes for manufacturing, testing, and release of vaccine and biologic products comply with cGMP and associated regulatory requirements.
  • Participate in internal and external audits and inspections, ensuring department compliance/readiness and serving as auditee for assigned areas of responsibility.
  • Identify, influence, and support compliance initiatives to improve compliance status and overall operational efficiency for batch release at the site.
  • Execute, review, approve, or support deviation/CAPA activities, change controls, complaints, data integrity, quality agreements, supplier/material qualification, cleaning verification/validation, Quality Risk Management processes, and other documentation, including generation, investigation, documentation, implementation, verification, closure, effectiveness, and trending where required for the Quality Department and supporting functions.
  • Ensure and promote compliance with regulatory requirements.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Citybiz
Oct 20th, 2026
Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors.

Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors. October 20, 2026 Enoch Kariuki Epicrispr Biotechnologies, a clinical-stage biotechnology company developing epigenetic therapies, has appointed Enoch Kariuki, PharmD, to its Board of Directors as the company advances its lead treatment candidate, EPI-321, toward pivotal clinical development and expands its pipeline of gene-modulating medicines. Kariuki brings extensive experience in biotechnology operations, corporate strategy, capital markets and business development. Throughout his career, he has participated in more than $10 billion in strategic financings and mergers and acquisitions across the life sciences industry. His appointment strengthens Epicrispr's board as the company works to advance its clinical programs, evaluate development priorities and establish the financial and operational infrastructure needed to support future growth. "Enoch is an accomplished biotechnology leader with a proven track record of building and scaling companies, guiding programs through pivotal clinical and regulatory milestones, and executing strategic transactions that create lasting value," said Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies. Salzman said Kariuki's combination of operational, financial and strategic experience will support the company's efforts to advance EPI-321 and develop additional epigenetic medicines. Kariuki currently serves as President of Endeavor BioMedicines, where he oversees corporate strategy and operations. His responsibilities include guiding organizational development and supporting the company's business and clinical development objectives. Previously, he served as CEO of Lengo Therapeutics, a biotechnology company acquired by Blueprint Medicines. He also held the position of Chief Financial Officer at VelosBio, which was acquired by Merck. Earlier in his career, Kariuki was Senior Vice President of Corporate Development at Synthorx, where he led the company's initial public offering and played a significant role in its subsequent acquisition by Sanofi. His experience also includes investment and advisory positions at H.I.G. Capital, Leerink Partners and UBS Investment Bank, providing a background in financing, strategic transactions and biotechnology investment analysis. These roles have given Kariuki experience across multiple stages of biotechnology company development, from securing financing and establishing corporate strategy to executing acquisitions and supporting clinical-stage growth. At Epicrispr, that experience will be relevant as the company evaluates the resources, partnerships and development strategies required to advance its therapeutic programs. Epicrispr's lead candidate, EPI-321, is being evaluated in clinical trials for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease characterized by progressive muscle weakness. The company is developing EPI-321 using its proprietary Gene Expression Modulation System (GEMS), an epigenetic technology platform designed to regulate gene expression without directly changing the underlying DNA sequence. Epigenetic therapies seek to influence how genes are activated or suppressed. Epicrispr's approach is intended to provide precise and durable modulation of gene activity, potentially addressing diseases associated with abnormal gene expression. The company is initially concentrating on neuromuscular disorders while developing additional gene-modulating treatments for other conditions. Advancing EPI-321 toward pivotal development represents an important operational priority. Clinical-stage biotechnology companies approaching later-stage trials must address study design, regulatory engagement, manufacturing readiness, financing requirements and long-term commercialization planning. Board members with experience in clinical development and capital markets can provide oversight as management evaluates those requirements and determines how to allocate resources across its pipeline. "Epicrispr is at an exciting inflection point, with compelling early clinical data supporting the potential of its differentiated epigenetic platform to address diseases with significant unmet medical needs," Kariuki said. He identified EPI-321's development in FSHD and the company's broader epigenetic technology platform as areas of opportunity, while emphasizing his intention to support Epicrispr's strategic priorities. In addition to his executive responsibilities, Kariuki serves on the boards of Zentalis Pharmaceuticals and Pheon Therapeutics, chairing the audit committees at both companies. He previously served on the boards of Imago Biosciences and ProfoundBio, which were acquired by Merck and Genmab, respectively. His board experience includes financial oversight and corporate governance responsibilities relevant to biotechnology companies operating in capital-intensive research and development environments. Kariuki earned a Doctor of Pharmacy degree from Texas Southern University and an MBA from the Tuck School of Business at Dartmouth College. He also completed a postdoctoral fellowship in research and development strategy and analytics at Bristol Myers Squibb. Epicrispr continues to advance EPI-321 through clinical development while expanding its portfolio of gene-modulating therapies. Kariuki's appointment adds biotechnology financing, transaction and operational experience to the board as the company prepares for its next stage of clinical development and evaluates opportunities to advance its epigenetic medicines platform.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.